L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

Antimicrobial Agents and Chemotherapy

Volumn 39, Issue 12, 1995, Pages 2602-2605

  Young, S D ^a   Britcher, S F ^a   Tran, L O ^a   Payne, L S ^a   Lumma, W C ^a   Lyle, T A ^a   Huff, J R ^a   Anderson, P S ^a   Olsen, D B ^a   Carroll, S S ^a   Pettibone, D J ^a   O'Brien, J A ^a   Ball, R G ^a   Balani, S K ^a   Lin, J H ^a   Chen, I W ^a   Schleif, W A ^a   Sardana, V V ^a   Long, W J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 4 CYCLOPROPYLETHYNYL 1,4 DIHYDRO 4 TRIFLUOROMETHYL 2H 3,1 BENZOXAZIN 2 ONE; EFAVIRENZ; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CHIMPANZEE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG MANUFACTURE; DRUG POTENCY; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RHESUS MONKEY; VIRUS INHIBITION; VIRUS MUTATION;

EID: 0028785708     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.39.12.2602     Document Type: Article

References (0)